12 results on '"Doneddu, Pietro"'
Search Results
2. Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP
- Author
-
Spina, Emanuele, Doneddu, Pietro Emiliano, Liberatore, Giuseppe, Cocito, Dario, Fazio, Raffaella, Briani, Chiara, Filosto, Massimiliano, Benedetti, Luana, Antonini, Giovanni, Cosentino, Giuseppe, Jann, Stefano, Mazzeo, Anna, Cortese, Andrea, Marfia, Girolama Alessandra, Clerici, Angelo Maurizio, Siciliano, Gabriele, Carpo, Marinella, Luigetti, Marco, Lauria, Giuseppe, Rosso, Tiziana, Cavaletti, Guido, Peci, Erdita, Tronci, Stefano, Ruiz, Marta, Piccinelli, Stefano Cotti, Schenone, Angelo, Leonardi, Luca, Gentile, Luca, Piccolo, Laura, Mataluni, Giorgia, Santoro, Lucio, Nobile-Orazio, Eduardo, and Manganelli, Fiore
- Published
- 2022
- Full Text
- View/download PDF
3. The neurophysiological lesson from the Italian CIDP database
- Author
-
Spina, Emanuele, Doneddu, Pietro Emiliano, Liberatore, Giuseppe, Cocito, Dario, Fazio, Raffaella, Briani, Chiara, Filosto, Massimiliano, Benedetti, Luana, Antonini, Giovanni, Cosentino, Giuseppe, Jann, Stefano, Mazzeo, Anna, Cortese, Andrea, Marfia, Girolama Alessandra, Clerici, Angelo Maurizio, Siciliano, Gabriele, Carpo, Marinella, Luigetti, Marco, Lauria, Giuseppe, Rosso, Tiziana, Cavaletti, Guido, Peci, Erdita, Tronci, Stefano, Ruiz, Marta, Piccinelli, Stefano Cotti, Schenone, Angelo, Leonardi, Luca, Gentile, Luca, Piccolo, Laura, Mataluni, Giorgia, Santoro, Lucio, Nobile-Orazio, Eduardo, and Manganelli, Fiore
- Published
- 2022
- Full Text
- View/download PDF
4. A diagnostic score for anti-MAG neuropathy or CIDP in patients with anti-MAG antibody
- Author
-
Doneddu, Pietro E, Ruiz, Marta, Bianchi, Elisa, Liberatore, Giuseppe, Manganelli, Fiore, Cocito, Dario, Cosentino, Giuseppe, Benedetti, Luana, Marfia, Girola A, Filosto, Massimiliano, Briani, Chiara, Giannotta, Claudia, and Nobile-Orazio, Eduardo
- Subjects
chronic inflammatory demyelinating polyradiculoneuropathy ,antibody ,diagnostic criteria ,neuropathy ,CIDP ,MAG - Published
- 2022
5. A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody.
- Author
-
Doneddu, Pietro E., Ruiz, Marta, Bianchi, Elisa, Liberatore, Giuseppe, Manganelli, Fiore, Cocito, Dario, Cosentino, Giuseppe, Benedetti, Luana, Marfia, Girola A., Filosto, Massimiliano, Briani, Chiara, Giannotta, Claudia, and Nobile‐Orazio, Eduardo
- Subjects
- *
CHRONIC inflammatory demyelinating polyradiculoneuropathy , *POLYNEUROPATHIES , *MYELIN sheath diseases , *NEUROPATHY - Abstract
Background and purpose: A diagnostic score was developed to discriminate anti‐myelin‐associated‐glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti‐MAG neuropathy. Methods: The clinical and electrophysiological features of patients with a diagnosis of typical anti‐MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups. Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature. A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti‐MAG antibody titers (CIDP‐MAG). Results: Thirty‐one anti‐MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP‐MAG patients were included. Scores in anti‐MAG antibody patients ranged from 1 to 5 and in CIDP patients from −7 to −1. Using the score, 4/16 CIDP‐MAG patients were diagnosed to have anti‐MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP‐MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti‐MAG neuropathy patients. Conclusions: Our score allowed an accurate discrimination to be made, amongst patients with anti‐MAG antibodies, of those affected by CIDP and the patients with anti‐MAG neuropathy. This score may help proper treatment to be chosen for patients with anti‐MAG antibodies with a CIDP‐like presentation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Risk factors for CIDP: antecedent events, lifestyle and dietary habits. Data from the Italian CIDP database
- Author
-
Doneddu, Pietro E, Bianchi, Elisa, Cocito, Dario, Manganelli, Fiore, Fazio, Raffaella, Filosto, Massimiliano, Mazzeo, Anna, Cosentino, Giuseppe, Cortese, Andrea, Jann, Stefano, Clerici, Angelo M, Antonini, Giovanni, Siciliano, Gabriele, Luigetti, Marco, Marfia, Girolama A, Briani, Chiara, Lauria, Giuseppe, Rosso, Tiziana, Cavaletti, Guido, Carpo, Marinella, Benedetti, Luana, Beghi, Ettore, Liberatore, Giuseppe, Santoro, Lucio, Peci, Erdita, Tronci, Stefano, Piccinelli, Stefano Cotti, Toscano, Antonio, Piccolo, Laura, Verrengia, Elena P, Leonardi, Luca, Schirinzi, Erika, Mataluni, Giorgia, Ruiz, Marta, Dacci, Patrizia, and Nobile-Orazio, Eduardo
- Subjects
Epidemiology ,Vaccination ,CIDP ,Chronic inflammatory demyelinating neuropathy ,Diet ,Lifestyle, Infections ,Lifestyle ,Infections - Published
- 2019
7. Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy.
- Author
-
Sotgiu, Stefano, Onida, Ilaria, Magli, Giorgio, Castiglia, Paolo, Conti, Marta, Nuvoli, Angela, Carta, Alessandra, Festa, Silvia, Dessì, Veronica, Doneddu, Pietro E., and Nobile-Orazio, Eduardo
- Subjects
MOTOR neuron diseases ,EPIDEMIOLOGY ,EUROPEAN integration ,PERIPHERAL nervous system ,AGE groups ,CHRONIC inflammatory demyelinating polyradiculoneuropathy - Abstract
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and disabling immunomediated radiculoneuropathy. Its worldwide epidemiology is heterogeneous and, in adults, CIDP prevalence varies from 0.6 to 9 cases per 100,000 population. Juvenile CIDP (jCIDP) is even rarer, with age-specific prevalence rates varying from 0.23 to 1.26 owing to different diagnostic criteria (American Academy of Neurology [AAN] and European Federation of Neurological Societies/Peripheral Nerve Society [EFNS/PNS]), different age grouping or, genuine differences. Objectives We assessed jCIDP incidence and prevalence in Sardinia, an area at very-high risk for autoimmune diseases, using comparable methods. Design The study area was the northern Sardinia, insular Italy, with 491,571 inhabitants and a pediatric population (0–18 years) of 79,086 individuals. Results On prevalence day (December 31, 2019) the total crude, age-specific prevalence rate were 6.32 per 100,000 according with AAN criteria, 7.58 per 100,000 population with European Neuromuscular Center (ENMC) criteria, and 8.85 per 100,000 population with both 2006 and 2010 EFNS/PNS criteria. Crude mean incidence rate were 0.42 per 100,000 per year with AAN criteria, 0.50 per 100,000 per year with ENMC criteria, and 0.59 per 100,000 per year using 2006 and 2010 EFNS/PNS criteria. Of the eight patients, six had typical CIDP, one had multifocal-acquired demyelinating sensory and motor neuropathy (MADSAM), and one chronic immune sensory polyradiculopathy (CISP). Patient's disability was generally mild. Clinical course was progressive, monophasic, or relapsing. Conclusion jCIDP prevalence and incidence rates in Sardinia were criteria-dependent, the lowest obtained when using AAN criteria, the highest using the EFNS/PNS. Nonetheless, even with the exclusion of the "possible" category, by using comparable methodology, prevalence rates in Sardinia are considerably higher than the range reported in all previous jCIDP studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy.
- Author
-
Doneddu, Pietro Emiliano, Mandia, Daniele, Gentile, Francesco, Gallia, Francesca, Liberatore, Giuseppe, Terenghi, Fabrizia, Ruiz, Marta, and Nobile‐Orazio, Eduardo
- Subjects
- *
THERAPEUTIC use of immunoglobulins , *CHRONIC diseases , *GRIP strength , *HEALTH surveys , *HOME care services , *IMMUNOGLOBULINS , *EVALUATION of medical care , *MOTOR neuron diseases , *HEALTH outcome assessment , *PATIENT monitoring , *POLYNEUROPATHIES , *GUILLAIN-Barre syndrome , *QUALITY of life , *QUESTIONNAIRES , *DECISION making in clinical medicine , *CASE-control method , *MUSCLE weakness , *DESCRIPTIVE statistics - Abstract
To evaluate the utility of different outcome measures to monitor dose adjustment of intravenous immunoglobulin (IVIg) therapy in patients with chronic inflammatory neuropathy (CIN). We assessed the adjustment of IVIg maintenance therapy in 20 patients (10 CIDP and 10 MMN) by regularly monitoring grip strength (GS) using a Martin Vigorimeter, RODS, and quality of life using the SF‐36 questionnaire. These measures were regularly performed by the patient at home. We also assessed the extended MRC sumscore (eMRC sumscore) at each outpatient visit for IVIg infusion. We also enrolled 30 healthy controls to measure any possible training effect of GS with time and to analyze random fluctuation of GS. Clinically relevant change was detected by eMRC sumscore in 14 (93%) patients, by RODS in 11 (73%) patients, and by GS in 8 (53%) patients. Early sensitivity was greatest for RODS (73%), followed by GS (53%), and eMRC sumscore (27%). This differed from CIDP, with an early change in RODS in 100% of patients, and MMN with an early change in GS in 75%. None of the outcome measures alone was sufficient to detect clinically significant changes in all patients. Home monitoring of outcome measures objectively assisted clinical decision during individualization of IVIg treatment. We recommend a multimodal approach using different outcome measures to monitor the individual patient with CIN. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Impact of environmental factors and physical activity on disability and quality of life in CIDP.
- Author
-
Doneddu, Pietro Emiliano, Bianchi, Elisa, Cocito, Dario, Manganelli, Fiore, Fazio, Raffaella, Filosto, Massimiliano, Beghi, Ettore, Mazzeo, Anna, Cosentino, Giuseppe, Cortese, Andrea, Jann, Stefano, Clerici, Angelo Maurizio, Antonini, Giovanni, Siciliano, Gabriele, Marfia, Girolama Alessandra, Briani, Chiara, Lauria, Giuseppe, Rosso, Tiziana, Cavaletti, Guido, and Carpo, Marinella
- Subjects
- *
PHYSICAL activity , *DISABILITIES , *QUALITY of life , *FOOD habits , *SYMPTOMS , *CHILDREN with disabilities , *ORAL habits - Abstract
A few observational studies and randomized trials suggest that exercise and rehabilitation may improve activity limitation and quality of life (QoL) in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), but the impact of other modifiable factors on the severity of the disease is not well understood. Using a structured questionnaire, we collected data on lifestyle and dietary habits of the patients included in the Italian CIDP database to investigate the possible influence of modifiable lifestyle factors on disability and QoL. Questionnaire data were available for 323 patients. The effect of lifestyle and dietary exposures on impairment, disability and QoL was evaluated using logistic regression models, adjusting for age, sex, disease duration, physical activity and smoking. Physical activity was associated with lower sensory impairment by the ISS scale, less disability by the INCAT and RODS scale and a better QoL in all the domains of EURO-QoL scale with the exception of anxiety/depression. None of the other parameters had an impact on these scales. This study adds evidence to the possible role of physical activity in improving symptom severity, disability and QoL in patients with CIDP. None of the other environmental factors investigated appeared to have an impact on the severity and health perception of CIDP. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Daily grip strength response to intravenous immunoglobulin in chronic immune neuropathies.
- Author
-
Doneddu, Pietro E. and Hadden, Robert D.M.
- Abstract
Introduction: Monitoring grip strength at home may detect improvement between intravenous immunoglobulin (IVIg) treatments in patients with chronic inflammatory neuropathies (CINs).Methods: Fifteen patients recorded grip strength each day, from one IVIg treatment until the next. We analyzed grip strength changes comparing thresholds of 8 kPa and 14 kPa. "Random" fluctuations of grip strength were distinguished from treatment response by smoothing the data.Results: "Random" fluctuations of at least 8 kPa occurred in 27% of patients. Smoothed daily grip strength increased by at least 8 kPa above baseline in 11 (73%) patients. Grip strength increased by at least 8 kPa for 3 consecutive days in 9 (60%) patients, and 5-day block mean increased by at least 8 kPa in 10 (67%) patients.Discussion: Home monitoring of grip strength confirmed treatment response in most patients with CINs on IVIg. To detect improvement in an individual patient, we suggest a threshold of at least 8 kPa on 3 consecutive days or on 5-day block mean. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
11. A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody
- Author
-
Pietro E. Doneddu, Marta Ruiz, Elisa Bianchi, Giuseppe Liberatore, Fiore Manganelli, Dario Cocito, Giuseppe Cosentino, Luana Benedetti, Girola A. Marfia, Massimiliano Filosto, Chiara Briani, Claudia Giannotta, Eduardo Nobile‐Orazio, Doneddu, Pietro E, Ruiz, Marta, Bianchi, Elisa, Liberatore, Giuseppe, Manganelli, Fiore, Cocito, Dario, Cosentino, Giuseppe, Benedetti, Luana, Marfia, Girola A, Filosto, Massimiliano, Briani, Chiara, Giannotta, Claudia, and Nobile-Orazio, Eduardo
- Subjects
antibody ,chronic inflammatory demyelinating polyradiculoneuropathy ,CIDP ,diagnostic criteria ,MAG ,neuropathy ,Neurology ,Settore MED/26 - Neurologia ,Neurology (clinical) ,Settore MED/26 - Abstract
Background and purpose: A diagnostic score was developed to discriminate anti-myelin-associated-glycoprotein (MAG) neuropathy from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and applied it to patients with atypical anti-MAG neuropathy. Methods: The clinical and electrophysiological features of patients with a diagnosis of typical anti-MAG neuropathy were compared to those of patients with a diagnosis of CIDP. The association of each feature with the diagnosis was assessed in the two groups. Features showing a significant association with the diagnosis were included in a multivariable logistic regression model and adjusted odds ratios were estimated for each feature. A score ranging from 1 to 3 was applied to each feature based on the magnitude of the estimated odds ratios. The score was then applied to patients with a clinical diagnosis of CIDP who also had high anti-MAG antibody titers (CIDP-MAG). Results: Thirty-one anti-MAG neuropathy patients, 45 typical CIDP patients and 16 CIDP-MAG patients were included. Scores in anti-MAG antibody patients ranged from 1 to 5 and in CIDP patients from -7 to -1. Using the score, 4/16 CIDP-MAG patients were diagnosed to have anti-MAG neuropathy and 12/16 patients to have CIDP. Response to intravenous immunoglobulin in the CIDP-MAG patients classified as CIDP was similar to that of definite CIDP patients and higher than that of anti-MAG neuropathy patients. Conclusions: Our score allowed an accurate discrimination to be made, amongst patients with anti-MAG antibodies, of those affected by CIDP and the patients with anti-MAG neuropathy. This score may help proper treatment to be chosen for patients with anti-MAG antibodies with a CIDP-like presentation.
- Published
- 2022
12. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database
- Author
-
Pietro Emiliano, Doneddu, Dario, Cocito, Fiore, Manganelli, Raffaella, Fazio, Chiara, Briani, Massimiliano, Filosto, Luana, Benedetti, Anna, Mazzeo, Girolama Alessandra, Marfia, Andrea, Cortese, Brigida, Fierro, Stefano, Jann, Ettore, Beghi, Angelo Maurizio, Clerici, Marinella, Carpo, Angelo, Schenone, Marco, Luigetti, Giuseppe, Lauria, Giovanni, Antonini, Tiziana, Rosso, Gabriele, Siciliano, Guido, Cavaletti, Giuseppe, Liberatore, Lucio, Santoro, Erdita, Peci, Stefano, Tronci, Marta, Ruiz, Stefano, Cotti Piccinelli, Antonio, Toscano, Giorgia, Mataluni, Laura, Piccolo, Giuseppe, Cosentino, Mario, Sabatelli, Eduardo, Nobile-Orazio, Claudia, Balducci, Doneddu, P, Cocito, D, Manganelli, F, Fazio, R, Briani, C, Filosto, M, Benedetti, L, Mazzeo, A, Marfia, G, Cortese, A, Fierro, B, Jann, S, Beghi, E, Clerici, A, Carpo, M, Schenone, A, Luigetti, M, Lauria, G, Antonini, G, Rosso, T, Siciliano, G, Cavaletti, G, Liberatore, G, Santoro, L, Peci, E, Tronci, S, Ruiz, M, Cotti Piccinelli, S, Toscano, A, Mataluni, G, Piccolo, L, Cosentino, G, Sabatelli, M, Nobile-Orazio, E, Doneddu, Pietro Emiliano, Cocito, Dario, Manganelli, Fiore, Fazio, Raffaella, Briani, Chiara, Filosto, Massimiliano, Benedetti, Luana, Mazzeo, Anna, Marfia, Girolama Alessandra, Cortese, Andrea, Fierro, Brigida, Jann, Stefano, Beghi, Ettore, Clerici, Angelo Maurizio, Carpo, Marinella, Schenone, Angelo, Luigetti, Marco, Lauria, Giuseppe, Antonini, Giovanni, Rosso, Tiziana, Siciliano, Gabriele, Cavaletti, Guido, Liberatore, Giuseppe, Santoro, Lucio, Peci, Erdita, Tronci, Stefano, Ruiz, Marta, Cotti Piccinelli, Stefano, Toscano, Antonio, Mataluni, Giorgia, Piccolo, Laura, Cosentino, Giuseppe, Sabatelli, Mario, and Nobile-Orazio, Eduardo
- Subjects
Adult ,Male ,Treatment response ,lewis-sumner syndrome ,Adolescent ,Databases, Factual ,Disease duration ,chronic inflammatory demyelinating polyradiculoneuropathy ,CIDP ,diagnostic criteria ,distal acquired demyelinating symmetric neuropathy ,Surgery ,Neurology (clinical) ,Psychiatry and Mental Health ,Kaplan-Meier Estimate ,computer.software_genre ,Disease course ,Young Adult ,lewis–sumner syndrome ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,In patient ,Child ,Aged ,Retrospective Studies ,Aged, 80 and over ,Retrospective review ,Database ,business.industry ,Polyradiculoneuropathy ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,surgery ,neurology ,psychiatry and mental health ,Italy ,Polyradiculoneuropathy, Chronic Inflammatory Demyelinating ,Disease Progression ,Female ,Settore MED/26 - Neurologia ,Progression rate ,business ,computer ,030217 neurology & neurosurgery - Abstract
ObjectivesA few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.MethodsWe applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.ResultsAt the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 (18%) had atypical CIDP, including 34 (7%) with distal acquired demyelinating symmetric neuropathy (DADS), 17 (4%) with purely motor, 17 (4%) with Lewis-Sumner syndrome (LSS) and 16 (3.5%) with purely sensory CIDP. Based on retrospective review of the symptoms and signs present at onset and for at least 1 year, 180 (39%) patients had an initial diagnosis compatible with atypical CIDP that in 96 (53%) patients evolved to typical CIDP. Mean disease duration was longer in patients evolving to typical CIDP than in those not evolving (p=0.0016). Patients with DADS and LSS had a less frequent response to immunoglobulin than those with typical CIDP, while patients with purely motor and sensory CIDP had a similar treatment response.ConclusionsThe proportion of patients with atypical CIDP varies during the disease course. DADS and LSS have a less frequent response to intravenous immunoglobulin compared with typical CIDP, raising the possibility of a different underlying pathogenetic mechanism.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.